MRJP rose tablet candies to improve ovarian function and uterine lining receptivity
A Randomized Controlled Study on the Effect of MRJPs on Improving Ovarian Function and Endometrial Receptivity
This will test whether daily oral MRJP rose tablet candies can help women aged 20–45 with diminished ovarian reserve or thin endometrium improve ovarian hormones and make the uterine lining more receptive.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 66 (estimated) |
| Ages | 20 Years to 45 Years |
| Sex | Female |
| Sponsor | The Fourth Affiliated Hospital of Zhejiang University School of Medicine Academic / other |
| Locations | 1 site (Yiwu, Zhejiang) |
| Trial ID | NCT07246733 on ClinicalTrials.gov |
What this trial studies
This randomized, placebo-controlled study gives eligible women either oral MRJP rose tablet candies or a matching placebo and follows them through the treatment period to measure reproductive and safety outcomes. Key measurements include serum hormones (estradiol, progesterone, FSH, LH), endometrial thickness, and expression of estrogen and progesterone receptor genes. Participants with royal jelly allergy, recent hormone therapy, pregnancy, breastfeeding, or severe chronic/endocrine disease are excluded. The trial is conducted at a single site: The Fourth Affiliated Hospital of Zhejiang University School of Medicine in Yiwu, Zhejiang.
Who should consider this trial
Good fit: Women aged 20–45 with regular menstrual cycles who have diminished ovarian reserve or thin endometrium, are not pregnant or breastfeeding, and are not allergic to royal jelly are the intended participants.
Not a fit: Women who are allergic to royal jelly, pregnant or breastfeeding, have recent hormone replacement therapy, or have severe chronic or endocrine disorders are excluded and unlikely to benefit from this intervention.
Why it matters
Potential benefit: If successful, MRJP candies could offer a non-hormonal, oral option to improve ovarian hormone balance and increase endometrial thickness, potentially supporting fertility.
How similar studies have performed: Preclinical work and small clinical reports suggest MRJPs can affect hormone levels, inflammation, and endometrial parameters, but large randomized trials confirming clinical fertility benefits are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Fertile women, aged 20 to 45 years old, with regular and normal menstrual cycles. Exclusion Criteria: * ① Allergic to royal jelly or its components; ② Suffering from severe chronic diseases or endocrine system disorders; ③ Pregnant or breastfeeding; ④ Undergoing hormone replacement therapy (HRT) within the last month
Where this trial is running
Yiwu, Zhejiang
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine — Yiwu, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: Xiaolin Wu
- Email: daringwxl@163.com
- Phone: +86-579-19548878600
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.